Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
Toshiya Nishi, Shinichi Kondo, Maki Miyamoto, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications
Irina A. Pikuleva, Nathalie Cartier
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 62
A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA)
Cecil D. Hahn, Yuwu Jiang, Vicente Villanueva, et al.
Epilepsia (2022) Vol. 63, Iss. 10, pp. 2671-2683
Open Access | Times Cited: 55
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Simona Lattanzi, Eugen Trinka, Emilio Russo, et al.
Drugs (2023) Vol. 83, Iss. 15, pp. 1409-1424
Open Access | Times Cited: 26
Pathophysiology to Risk Factor and Therapeutics to Treatment Strategies on Epilepsy
Ana Paula de Araújo Boleti, Pedro Henrique de Oliveira Cardoso, Breno Emanuel Farias Frihling, et al.
Brain Sciences (2024) Vol. 14, Iss. 1, pp. 71-71
Open Access | Times Cited: 17
Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
Nicole A. Hawkins, Manuel Jurado, Tyler Thaxton, et al.
Epilepsia (2021) Vol. 62, Iss. 11, pp. 2845-2857
Open Access | Times Cited: 50
Epilepsy in Dravet Syndrome—Current and Future Therapeutic Opportunities
Chao Gao, Mikolaj Pielas, Fuyong Jiao, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2532-2532
Open Access | Times Cited: 20
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies
Jonathan J. Halford, Michael R. Sperling, Dimitrios Arkilo, et al.
Epilepsy Research (2021) Vol. 174, pp. 106646-106646
Open Access | Times Cited: 41
The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results
Cecilie Johannessen Landmark, Heidrun Potschka, Stéphane Auvin, et al.
Epilepsia (2021) Vol. 62, Iss. 4, pp. 857-873
Open Access | Times Cited: 38
Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H)
Tatsuki Koike, Masato Yoshikawa, Haruhi Kamisaki Ando, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 16, pp. 12228-12244
Open Access | Times Cited: 38
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder
Heather E. Olson, Carolyn I. Daniels, Isabel Haviland, et al.
Journal of Neurodevelopmental Disorders (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Anticonvulsive properties of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor
Toshiya Nishi, Cameron S. Metcalf, Shinji Fujimoto, et al.
Epilepsia (2022) Vol. 63, Iss. 6, pp. 1580-1590
Open Access | Times Cited: 26
Assessment of cholesterol homeostasis in the living human brain
Ahmed Haider, Chunyu Zhao, Lu Wang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 665
Open Access | Times Cited: 26
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment
William Hong, Isabel Haviland, Elia M. Pestana-Knight, et al.
CNS Drugs (2022) Vol. 36, Iss. 6, pp. 591-604
Open Access | Times Cited: 24
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies
Graeme J. Sills
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 16
Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI):II. Drugs in more advanced clinical development
Meir Bialer, Svein I. Johannessen, Matthias J. Koepp, et al.
Epilepsia (2022) Vol. 63, Iss. 11, pp. 2883-2910
Closed Access | Times Cited: 21
The potential of CYP46A1 as a novel therapeutic target for neurological disorders: An updated review of mechanisms
Mohaddeseh Sadat Alavi, Gholamreza Karimi, Hussein A. Ghanimi, et al.
European Journal of Pharmacology (2023) Vol. 949, pp. 175726-175726
Closed Access | Times Cited: 13
Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)
Scott Demarest, Shafali Jeste, Nitin Agarwal, et al.
Epilepsy & Behavior (2023) Vol. 142, pp. 109173-109173
Closed Access | Times Cited: 12
Research Progress on Precise Diagnosis and Treatment of Developmental and Epileptic Encephalopathies
涵 杨
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 6-12
Closed Access
A review of the putative antiseizure and antiepileptogenic mechanisms of action for soticlestat
Shinichi Kondo, Venkatesha Murthy, Mahnaz Asgharnejad, et al.
Epilepsia (2025)
Open Access
New Directions in Neurosteroid Therapeutics in Neuropsychiatry
Charles F. Zorumski, Douglas F. Covey, Yukitoshi Izumi, et al.
Neuroscience & Biobehavioral Reviews (2025), pp. 106119-106119
Open Access
Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
Hongxia Jia, T. Eric Ballard, Liming Zhang, et al.
Clinical Pharmacology in Drug Development (2025)
Open Access
Design and identification of brain-penetrant, potent, and selective 1,3-oxazole-based cholesterol 24-hydroxylase (CH24H) inhibitors
Y. ITO, Eiji Kimura, Izumi Nomura, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118182-118182
Open Access
The role of glutamate receptors and transporters in epilepsy: evidence from animal studies
Jéssica A. Lemes, Barbara dos Anjos Rosário, Silvia de Oliveira Rocha, et al.
Reviews in the Neurosciences (2025)
Closed Access
Efficacy, safety, and tolerability of soticlestat (TAK-935) as adjunctive therapy in pediatric patients with dravet syndrome and Lennox–Gastaut syndrome: a meta-analysis of 3 randomized controlled trials
Lanlan Zhang, Jean Nana, Chengzhong Wang
Frontiers in Pharmacology (2025) Vol. 16
Open Access
The Epilepsy Drug Pipeline: Update on Near-to-Market Therapies
Christopher Elder, Jacob Pellinen, Samuel W. Terman
Seminars in Neurology (2025) Vol. 45, Iss. 02, pp. 287-297
Closed Access
Page 1 - Next Page

Scroll to top